Menu Search
Equities

Bio-Techne Corp

TE1:MUN

Bio-Techne Corp

Actions
  • Price (EUR)71.00
  • Today's Change2.00 / 2.90%
  • Shares traded--
  • 1 Year change+6.77%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bio-Techne Corporation is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities. The Company's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.

  • Revenue in USD (TTM)1.16bn
  • Net income in USD168.07m
  • Incorporated1981
  • Employees3.10k
  • Location
    Bio-Techne Corp614 MCKINLEY PL N EMINNEAPOLIS 55413United StatesUSA
  • Phone+1 (612) 379-8854
  • Fax+1 (612) 656-4400
  • Websitehttps://www.bio-techne.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.